Clinical toxicity of antiretroviral nucleoside analogs

Antiviral Research

Volumn 31, Issue 3, 1996, Pages 121-135

  Styrt, Barbara A ^a,b   Piazza Hepp, Toni D ^a   Chikami, Gary K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Didanosine; Lamivudine; Nucleoside analogs, retroviral; Stavudine; Toxicity, nucleoside analogs; Zalcitabine; Zidovudine

Indexed keywords

DIDANOSINE; LAMIVUDINE; NUCLEOTIDE ANALOG; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

DRUG SURVEILLANCE PROGRAM; DRUG TOXICITY; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0030199966     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(96)85209-0     Document Type: Article

References (122)

1. Abrams, D.I., Goldman, A.I., Launer, C., Korvick, J.A., Neaton, J.D., Crane, L.R., Grodesky, M., Wakefield, S., Muth, K., Kornegay, S., Cohn, D.L., Harris, A., Luskin-Hawk, R., Markowitz, N., Sampson, J.H., Thompson, M., Deyton, L. and the Terry Beirn Community Programs for Clinical Research on AIDS (1994) A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N. Engl. J. Med. 330, 657-662.
2. Albrecht, H., Stellbrink, H.-H. and Arasteh, K. (1993) Didanosine-induced disorders of glucose tolerance. Ann. Intern. Med. 119, 1050.
3. Allan, J.D., Connolly, K.J., Fitch, H., Jackson-Pope, L., McLaren, C., Canetta, R. and Groopman, J.E. (1993) Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. Clin. Infect. Dis. 16 (Suppl. 1), S46-S51.
4. Arnaudo, E., Dalakas, M., Shanske, S., Moraes, C.T., Di-Mauro, S. and Schon, E.A. (1991) Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337, 508-510.
5. Astagneau, P., Michon, C., Marche, C., Simonpoli, A.M., Girard, P.M., Kernbaum, S., Coulaud, J.P. and Saimot, A.G. (1990) Atteintes hépatiques au cours du SIDA. Ann. Med. Interne 141, 459-463.
6. Baum, C., Kweder, S.L. and Anello, C. (1994) The Spontaneous Reporting System in the United States. In: B.L. Strom (Ed), Pharmacoepidemiology (2nd edition), Ch. 10, pp. 125-137. Wiley, New York.
7. Berger, A.R., Arezzo, J.C., Schaumburg, H.H., Skowron, G., Merigan, T., Bozzette, S., Richman, D. and Soo, W. (1993) 2′,3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 43, 358-362.
8. Bissuel, F., Bruneel, F., Habersetzer, F., Chassard, D., Cotte, L., Chevallier, M., Bernuau, J., Lucet, J.-C. and Trepo, C. (1994) Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J. Intern. Med. 235, 367-372.
9. Blanche, S., Duliege, A.-M., Soledad Navarette, M., Tardieu, M., Debre, M., Rouzioux, C., Selfrup, J., Kouzan, S. and Griscell, C. (1991) Low-dose zidovudine in children with an human immunodeficiency virus type 1 infection acquired in the perinatal period. Pediatrics 88, 364-370.
10. Boag, F.C., Dean, R., Hawkins, D.A., Lawrence, A.G. and Gazzard, B.G. (1992) Abnormalities of liver function during HIV seroconversion illness. International Journal of STD and AIDS 3, 46-48.
11. Brahams, D. (1994) Deaths in US fialuridine trial. Lancet 343, 1494-1495.
12. Browne, M.J., Mayer, K.H., Chafee, S.B.D., Dudley, M.N., Posner, M.R., Steinberg, S.M., Graham, K.K., Geletko, S.M., Zinner, S.H., Denman, S.L., Dunkle, L.M., Kaul, S., McLaren, C., Skowron, G., Kouttab, N.M., Kennedy, T.A., Weitberg, A.B. and Curt, G.A. (1993) 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J. Infect. Dis. 167, 21-29.
13. Butler, K.M., Husson, R.N., Balis, F.M., Brouwers, P., Eddy, J., El-Amin, D., Gress, J., Hawkins, M., Jarosinski, P., Moss, H., Poplack, D., Santacroce, S., Venzon, D., Wiener, L., Wolters, P. and Pizzo, P.A. (1991) Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N. Engl. J. Med. 324, 137-144.
14. CDC (Centers for Disease Control and Prevention) (1995) USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 44(no. RR-8), 1-34.
15. Chalmers A.C., Greco, C.M. and Miller, R.G. (1991) Prognosis in AZT myopathy. Neurology 41, 1181-1184.
16. Chang, C.-N., Doong, S.-L. and Cheng, Y.-C. (1992a) Conversion of 5-iodo-2-pyrimidinone-2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design. Biochem. Pharmacol. 43, 2269-2273.
17. Chang, C.-N., Skalski, V., Zhou, J.H. and Cheng, Y.-C. (1992b) Biochemical pharmacology of ( + )- and ( - )-2′,3′,-dideoxy-3′-thiacytodine as anti-hepatitis B virus agents. J. Biol. Chem. 267, 22414-22420.
18. Chariot, P., Monnet, I. and Gherardi, R. (1993) Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy. Ann. Neurol. 34, 561-565.
19. Chattha, G., Arieff, A.I., Cummings, C. and Tierney Jr., L.M. (1993) Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann. Intern. Med. 118, 37-39.
20. Chen, C.-H. and Cheng, Y.-C. (1992) The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′,2′-dideoxycytidine. J. Biol. Chem. 267, 2858-2859.
21. Chen, C.-H., Vazquez-Padua, M. and Cheng, Y.-C. (1991) Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39, 625-628.
22. Chen, S.C.A., Barker, S.M., Mitchell, D.H., Stevens, S.M.B., O'Neill, P. and Cunningham, A.L. (1992) Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection. Pathology 24, 109-111.
23. Chidiac, C., Alfandari, S., Caron, J. and Mouton, Y. (1995) Diabetes mellitus following treatment of AIDS with didanosine. AIDS 9, 215-216.
24. Dalakas, M.C., Illa, I., Pezeshkpour, G.H., Laukaitis, J.P., Cohen, B. and Griffin, J.L. (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 322, 1098-1105.
25. D'Aquila, R.T., Johnson, V.A., Welles, S.L., Japour, A.J.., Kuritzkes, D.R., DeGruttola, V., Reichelderfer, P.S., Coombs, R.W., Crumpacker, C.S., Kahn, J.O. and Richman, D.D. (1995) Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122, 401-408.
26. de Jong, M.D. and Borleffs, J.C.C. (1992) Didanosine and heart failure. Lancet 339, 806-807.
27. Dienstag, J.L., Perrillo, R.P., Schiff, E.R., Bartholomew, M., Vicary, C. and Rubin, M. (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333, 1657-1661.
28. Dolin, R., Amato, D.A., Fischl, M.A., Pettinelli, C., Beltangady, M., Liou, S.-H., Brown, M.J., Cross, A.P., Hirsch, M.S., Hardy, W.D., Mildvan, D., Blair, D.C., Powderly, W.G., Para, M.F., Fife, K.H., Steigbigel, R.T., Smaldone, L. and the AIDS Clinical Trials Group. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Arch. Intern. Med. 155, 961-974.
29. Domanski, M.J., Sloas, M.M., Follmann, D.A., Scalise III, P.P., Tucker, E.E., Egan, D. and Pizzo, P.A. (1995) Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J. Pediatr. 127, 137-146.
30. Drusano, G.L., Balis, F.M., Gitterman, S.R. and Pizzo, P.A. (1994) Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob. Agents Chemother. 38, 1726-1731.
31. Dubin, G. and Braffman, M.N. (1989) Zidovudine-induced hepatotoxicity. Ann. Intern. Med. 110, 85-86.
32. Dubinsky, R.M., Yarchoan, R., Dalakas, M. and Broder, S. (1989) Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerve 12, 856-860.
33. Eron, J.J., Benoit, S.L., Jensek, J., MacArthur, R.D., Santana, J., Quinn, J.B., Kuritzkes, D.R., Fallon, M.A. and Rubin, M. (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333. 1662-1669.
34. Fischl, M.A., Richman, D.D., Causey, D.M., Grieco, M.H., Bryson, Y., Mildvan, D., Ladkin, O.L., Groopman, J.E., Volberding, P.A., Schooley, R.T., Jackson, G.G., Durack, D.T., Andrews, J.C., Nusinoff-Lehrman, S., Darry, D.W. and the AZT Collaborative Working Group (1989) Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 262, 2405-2410.
35. Fischl, M.A., Parker, C.B., Pettinelli, C., Wulfsohn, M., Hirsch, M.S., Collier, A.C., Antoniskis, D., Ho, M., Richman, D.D., Fuchs, E., Merigan, T.C., Reichman, R.C., Gold, J., Steigbigel, N., Leoung, G.S., Rasheed, S., Tsiatis, A. and the AIDS Clinical Trials Group. (1990a) A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 323, 1009-1014.
36. Fischl, M.A., Richman, D.D., Hansen, H., Collier, A.C., Carey, J.T., Para, M.F., Hardy, W.D., Dolin, R., Powderly, W.G., Allan, J.D., Wong, B., Merigan, T.C., McAuliffe, V.J., Hyslop, N.E., Rhame, F.S., Balfour Jr., H.H., Spector, S.A., Volberding, P., Pettinelli, C., Anderson, J. and the AIDS Clinical Trials Group (1990b) The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency type 1 (HIV) infection. Ann. Intern. Med. 112, 727-737.
37. Forseter, G., Joline, C. and Wormser, G.P. (1994) Tolerability. safety, and acceptability of zidovudine prophylaxis in health care workers. Arch. Intern. Med. 154, 2745-2749.
38. Fortgang, I.S., Belitsos, P.C., Chaisson, R.E. and Moore, R.D. (1995) Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am. J. Gastroenterol. 90, 1433-1436.
39. Freiman, J.P., Helfert, K.E., Hamrell, M.R. and Stein, D.S. (1993) Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 7, 379-385.
40. Gelmon, K., Montaner, J.S.G., Fanning, M., Smith. J.R.M., Falutz, J., Tsoukas, C., Gill, J., Wells, G., O'Shaughnessy, M., Wainberg, M. and Ruedy, J. (1989) Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 3, 555-561.
41. Gertner, E., Thurn, J.R., Williams, D.N., Simpson, M., Balfour Jr., H.H., Rhame, F. and Henry, K. (1989) Zidovudine-associated myopathy. Am. J. Med. 86, 814-818.
42. Gherardi, R.K., Florea-Strat, A., Fromont, G., Poron, F., Sabourin, J.-C. and Authier, J. (1994) Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1-alpha accumulation in mitochondria of AZT fibers. Ann. Neurol. 36, 752-758.
43. Gill, P.S., Harrington Jr., W., Kaplan, M.H., Ribeiro, R.C., Bennett, J.M., Liebman, H.A., Bernstein-Singer, M., Espina, B.M., Cabral, L., Allen, S., Kornblau, S., Pike, M.C. and Levine, A.M. (1995) Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 332, 1744-1748.
44. Gimenez, S., Bagheri, H., Marchou, B., Massip, P., Lafont, J., Sorbette, F., Armengaud, M. and Montastruc, J.L. (1990) Bilan d'un suivi de pharmacovigilance de la zidovudine. Therapie 45, 407-409.
45. Glasgow, B.J., Anders, K., Layfield, L.J., Steinsapir, K.D., Gitnick, G.L. and Lewin, K.J. (1985) Clinical and pathologic findings of the liver in the acquired immune deficiency syndrome (AIDS). Am. J. Clin. Pathol. 83, 582-588.
46. Goldin, R.D., Wilkins, M., Dourakis, S., Parkin, J., and Lindley, R. (1993) Iron overload in multiply transfused patients who are HIV seropositive. J. Clin. Pathol. 46, 1036-1038.
47. Gopinath, R., Hutcheon, M., Cheema-Dhadli, S. and Halperin, M. (1992) Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: biochemical studies. J. Am. Soc. Nephrol. 3, 1212-1219.
48. Gradon, J.D., Chapnick, E.K. and Sepkowitz, D.V. (1992) Zidovudine-induced hepatitis. J. Intern. Med. 231, 317-318.
49. Grasela, T.H., Walawander, C.A., Beltangady, M., Knupp, C.A., Martin, R.R., Dunkle, L.M., Barbhaiya, R.H., Pittman, K.A., Dolin, R., Valentine, F.T. and Liebman, H.A. (1994) Analysis of potential risk factors associated with the development of pancreatitis in Phase I patients with AIDS or AIDS-related complex receiving didanosine. J. Infect. Dis. 169, 1250-1255.
50. Grau, J.M., Masanes, F., Pedrol, E., Casademont, J., Fernandez-Sola, J. and Urbano-Marquez, A. (1993) Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Ann. Neurol. 34, 206-211.
51. Hayakawa, M., Ogawa, T., Sugiyama, S., Tanaka, M. and Ozawa, T. (1991) Massive conversion of guanosine to 8-hydroxy-guanosine in mouse liver mitochondrial DNA by administration of azidothymidine. Biochem. Biophys. Res. Commun. 176, 87-93.
52. Hermine, O., Bouscary, D., Gessain, A., Turlure, P., Leblond, V., Franck, N., Buzyn-Veil, A., Rio, B., Macintyre, E., Dreyfus, F. and Bazarbachi, A. (1995) Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 332, 1749-1751.
53. Herskowitz, A., Willoughby, S.B., Baughman, K.L., Schulman, S.P. and Bartlett, J.D. (1992) Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann. Intern. Med. 116, 311-313.
54. Herzberg, N.H., Zorn, I., Zwart, R., Portegies, P. and Bolhuis, P.A. (1992) Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine. Muscle Nerve 15, 706-710.
55. Izuta, S., Saneyoshi, M., Sakurai, T., Suzuki, M., Kojima, K. and Yoshida, S. (1991) The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms. Biochem. Biophys. Res. Commun. 179, 776-783.
56. Jacobson, M.A., McGrath, M.S., Joseph, P., Molaghan, J.B., Tadepalli, S. and Quinn, R. (1989) Zidovudine-induced fever. J. Acquired Immunodeficiency Syndromes 2, 382-388.
57. Kahn, J.O., Lagakos, S.W., Richman, D.D., Cross, A., Pettinelli, C., Kiou, S.-H., Brown, M., Volberding, P.A., Crumpacker, C.S., Beall, G., Sacks, H.S., Merigan, T.C., Beltangady. M., Smaldone. L., Dolin, R. and the NIAID AIDS Clinical Trials Group (1992) A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N. Engl. J. Med. 327, 581-587.
58. Kicburtz, K.D., Seidlin, M., Lambert, J.S., Dolin, R., Reichman, R. and Valentine, F. (1992) Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J. Acquired Immunodeficiency Syndromes 5, 60-64.
59. 9 L or less. Arch. Intern. Med. 152, 2286-2292.
60. Kozal, M.J., Kroodsma, K., Winters, M.A., Shafer. R.W., Efron, B., Katzenstein, D.A. and Merigan, T.C. (1994) Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine therapy. Ann. Intern. Med. 121, 263-268.
61. Lai, K.K., Gang, D.L., Zawacki, J.K. and Cooley, T.P. (1991) Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann. Intern. Med. 115, 283-284.
62. Lane, R.J.M., McLean, K.A., Moss, J. and Woodrow, D.F. (1993) Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions. Neuropathol. Appl. Neurobiol. 19, 406-413.
63. Larder, B.A., Darby, G. and Richman, D.D. (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734.
64. Le Bras, P., D'Oiron, R., Quertainmont, Y. and Caquet, R. (1994) Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? AIDS 8, 716-717.
65. Lee, B.L., Wong, D., Benowitz, N.L. and Sullam, P.M. (1993) Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 53, 529-535.
66. Lewis, L.D., Hamzeh, F.M. and Lietman. P.S. (1992) Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2′3′-dideoxycytidine. Antimicrob. Agents Chemother. 36, 2061-2065.
67. Lutton, J.D., Mathew, A., Levere, R.D and Abraham, N.G. (1990) Role of heme metabolism in AZT-induced bone marrow toxicity. Am. J. Hematol. 35, 1-5.
68. Manji, H., Harrison, M.J.G., Round, J.M., Jones, D.A., Connolly, S., Fowler, C.J., Williams, I. and Weller, I.V.D. (1993) Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine. J. Neurol. 240, 479-488.
69. Martin, J.L., Brown, C.E., Matthews-Davis, N. and Reardon, J.E. (1994) Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38, 2743-2749.
70. Marwick, C. (1994) NIH panel report of 'no flaws' in FIAU trial at variance with FDA report, new probe planned. JAMA 272, 9-11.
71. Mayers, D.L., Japour, A.J., Arduino, J.-M., Hammer, S.M., Reichman, R., Wagner, K.F., Chung, R., Lane, J., Crumpacker, C.S., McLeod, G.X., Beckett, L.A., Roberts, C.R., Winslow, D., Burke, D. and the RV43 Study Group. (1994) Dideoxynucleoside resistance emerges with prolonged zidovudine therapy. Antimicrob. Agents Chemother. 38. 307-314.
72. Maxson, C.J., Greenfield, S.M. and Turner, J.L. (1992) Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am. J. Gastroenterol. 87, 708-713.
73. McKinney Jr., R.E., Pizzo, P.A., Scott, G.B., Parks, W.P., Maha, M.A., Nusinoff Lehrman, S., Riggs, M., Eddy, J., Lane, B.A., Eppes, S.C., Wilfert, C.M. and the Pediatric Zidovudine Phase I Study Group (1990) J. Pediatr. 116, 640-647.
74. McKinney Jr., R.E., Maha, M.A., Connor, E.M., Feinberg, J., Scott, G.B., Wulfsohn, M., McIntosh, K., Borkowsky, W., Modlin, J.F., Weintrub, P., O'Donnell, K., Gelber, R.D., Knowlton Rogers, G., Nusinoff Lehrman, S., Wilfert, C.M. and the Protocol 043 Study Group (1991) A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus diase. N. Engl. J. Med. 324, 1018-1025.
75. McLeod, G.X. and Hammer, S.M. (1992) Zidovudine: five years later. Ann. Intern. Med. 117, 487-501.
76. Medina, D.J., Tsai, C.-H., Hsiung, G.D. and Cheng, Y.-C. (1994) Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in culture cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob. Agents Chemother. 38. 1824-1828.
77. Mhiri, C., Baudrimont, M., Bonne, G., Geny, C., Degoul, F., Marsac, C., Roullet, E. and Gherardi, R. (1991) Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol. 29, 606-614.
78. Miles, S.A., Mitsuyasu, R.T., Moreno, J., Baldwin, G., Alton, N.K., Souza, L. and Glaspy, J.A. (1991) Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 77, 2109-2117.
79. Modica-Napolitano, J.S. (1993) AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem. Biophys. Res. Commun. 194, 170-177.
80. Montaner, J.S.G., Rachlis, A., Beauliew, R., Gill, J., Schlech, W., Phillips, P., Auclair, C., Boulerice, F., Schindzielorz, A., Smaldone, L., Wainberg, M., Singer, J. and Schechter, M.T. (1994) Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program. J. Acquired Immune Deficiency Syndromes 7, 924-930.
81. Moore, R.D., Creagh-Kirk, T., Keruly, J., Link, G., Wang, M.-C., Richman, D., Chaisson, R.E. and the Zidovudine Epidemiology Study Group (1991) Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Arch. Intern. Med. 151, 981-986.
82. Moyle, G.J., Nelson, M.R., Hawkins, D. and Gazzard, B.C. (1993) The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT). Q. J. Med. 86, 155-163.
83. Nguyen, B.-Y., Yarchoan, R., Wyvill, K.M., Venzon, D.J., Pluda, J.M., Mitsuya, H. and Broder, S. (1995) Five-year follow-up of a Phase I study of didanosine in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171, 1180-1189.
84. Nielsen, K., Wei, L.S., Sim, M.-S., Deveikis, A., Keller, M., Stiehm, E.R., Frenkel, L.M. and Bryson, Y.J. (1995) Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay. J. Infect. Dis. 172, 359-364.
85. Olano, J.P., Borucki, M.J., Wen, J.W. and Haque, A.K. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin. Infect. Dis. 21, 973-976.
86. Panegyres, P.K., Papadimitriou, J.M., Hollingsworth, P.N., Armstrong, J.A. and Kakulas, B.A. (1990) Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment. J Neurol. Neurosurg. Psychiatr. 53, 649-655.
87. Parker, W.B. and Cheng, Y.C. (1994) Mitochondrial toxicity of antiviral nucleoside analogs. J. NIH Res. 6(3). 57-61.
88. Peters, B.S., Winer, J., Landon, D.N., Stotter, A. and Pinching, A.J. (1993) Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q. J. Med. 86, 5-15.
89. Pezeshkpour, G., Illa, I. and Dalakas, M.C. (1991) Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies. Hum. Pathol. 22, 1281-1288.
90. Physicians' Desk Reference (49th edition), Medical Economics, Montvale, NJ, 1995.
91. Pike, I.M. and Nicaise, C. (1993) The didanosine expanded access program: safety analysis. Clin. Infect. Dis. 16 (Suppl. 1), S63-S68.
92. Pizzo, P.A., Butler, K., Balis, F., Brouwers, E., Hawkins, M., Eddy, J., Einloth, M., Falloon, J., Husson, R., Jarosinski, P., Meer, J., Moss, H., Poplack, D.G., Santacroce, S., Wiener, L. and Wolters, P. (1990) Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J. Pediatr. 117, 799-808.
93. Pluda, J.M., Cooley, T.P., Montaner, J.S.G., Shay, L.E., Reinhalter, N.E., Warthan, S.N., Ruedy, J., Hirst, H.M., Vicary, C.A., Quinn, J.B., Yuen, G.J., Wainberg, M.A., Rubin, M. and Yarchoan, R. (1995) A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171, 1438-1447.
94. Pollack, S. and Weaver, J. (1993) Azidothymidine(AZT)-induced siderosis. Am. J. Hematol. 43, 230-233.
95. Puro, V., Ippolito, G., Guzzanti, E., Serafin, I., Pagano, G., Suter, F., Cristini, G., Arici, C., Angarano, G., Soscia, F., Vaglia, A., Bonazzi., L. and the Italian Study Group on Occupational Risk of HIV Infection (1992) Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. AIDS 6, 963-969.
96. Richman, D.D., Fischl, M.A., Grieco, M.H., Gottlieb, M.S., Volberding, P.A., Laskin, O.L., Leedom, J.M., Groopman, J.E., Mildvan, D., Hirsch, M.S., Jackson, G.G., Durack, D.T., Nusinoff-Lehrman, S. and the AZT Collaborative Working Group. (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317, 192-197.
97. Richman, D.D., Grimes, J.M. and Lagakos, S.W. (1990) Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J. Acquired Immune Deficiency Syndromes 3, 743-746.
98. Schmitz, S.H., Scheding, S., Voliotis, D., Rasokat, H., Diehl, V. and Schrappe, M. (1994) Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood. Ann. Hematol. 69, 135-138.
99. Schuurman, R., Hijhuis, M., van Leeuwan, R., Schipper, P., de Jong, D., Collis, P., Danner, S.A., Mulder, J., Loveday, C., Christopheraon, C., Kwok, S., Sninsky, J. and Boucher, C.A.B. (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171, 1411-1419.
100. Sheremata, W.A., Benedict, D., Squilacote, D.C., Sazant, A. and DeFreitas, E. (1993) High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology 43, 2125-2129.
101. Shintaku, M., Nasu, K. and Shimizu, T. (1993) Fulminant hepatic failure in an AIDS patient: possible zidovudine-induced hepatotoxicity. Am. J. Gastroenterol. 88, 464-466.
102. Shriner, K. and Bidwell Goetz, M. (1992) Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. Am. J. Med. 93, 94-96.
103. Simpson, D.M., Citak, K.A., Godfrey, E., Godbold, J. and Wolfe, D.E. (1993) Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology 43, 971-976.
104. Simpson, M.V., Chin, C.D., Keilbaugh, S.A., Lin, T.-S. and Prusoff, W.H. (1989) Studies on the inhibition of mitochondrial DNA replication by 3′-azido-3′-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication. Biochem. Pharmacol. 38, 1033-1036.
105. Skowron, B. (1995) Biologic effects and safety of stavudine: overview of Phase I and II clinical trials. J. Infect. Dis. 171 (Suppl. 2), S113-S117.
106. Snower, D.P. and Weil, S.C. (1993) Changing etiology of macrocytosis. Zidovudine as a frequent causative factor. Am. J. Clin. Pathol. 99, 57-60.
107. Stern, R.S. (1994) Epidemiology of skin disease in HIV infection: a cohort study of health maintenance organization members. J. Invest. Dermatol. 102, 34S-37S.
108. Styrt, B. and Freiman, J.P. (edited by J.H. Lewis) (1995) Hepatotoxicity of antiviral agents. Gastroenterol. Clin. N. Am. 24, 839-852.
109. Till, M. and MacDonell, K.B. (1990) Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine? Ann. Intern. Med. 113, 492-494.
110. Tokars, J.I., Marcus, R., Culver, D.H., Schable, C.A., McKibben, P.S., Bandea, C.I. and Bell, D.M. (1993) Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann. Intern. Med. 118, 913-919.
111. van Leeuwen, R., Katlama, C., Kitchen, V., Boucher, C.A.B., Tubiana, R., McBride, M., Ingrand, D., Weber, J., Hill, A., McDade, H. and Danner, S.A. (1995) Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171, 1166-1171.
112. Vittecoq, D., Zucman, D., Auperin, I. and Passeron, J. (1994) Transient insulin-dependent diabetes mellitus in an HIV-infected patient receiving didanosine. AIDS 8, 1351.
113. Volberding, P.A., Lagakos, S.W., Koch, M.A., Pettinelli, C., Myers, M.W., Booth, D.K., Balfour Jr., H.H., Reichman, R.C., Bartlett, J.A., Hirsch, M.S., Murphy, R.L, Hardy, W.D., Soeiro, R., Fischl, M.A., Bartlett, J.G., Merigan, T.C., Hyslop, N.E., Richman, D.D., Valentine, R.T., Corey, L. and the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. N. Engl. J. Med. 322, 941-949.
114. Wainberg, M.A., Salomon, H., Gu, Z., Montaner, J.S.G., Cooley, T.P., McCaffrey, R., Ruedy, J., Hirst, H.M., Cammack, N., Cameron, J. and Nicholson, W. (1995) Development of HIV-1 resistance to ( - )2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9, 351-357.
115. Walter, E.G., Drucker, R.P., McKinney, R.E. and Wilfert, C.M. (1991) Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy. J. Pediatr. 119, 152-155.
116. Warrier, I. and Lusher, J.M. (1990) Retrovir therapy in hemophilic children with symptomatic human immunodeficiency virus infection: efficacy and toxicity. Am. J. Pediatr. Hematol. Oncol. 12, 160-163.
117. Wassef, M. and Keiser, P. (1995) Hypersensitivity to zidovudine: report of a case of anaphylaxis and review of the literature. Clin. Infect. Dis. 20, 1387-1389.
118. Weissman, J.D., Constantinitis, I., Hudgine, P. and Wallace, D.C. (1992) 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients. Neurology 42, 619-623.
119. Wetton, C.W.N., Goldin, R. and Crofton, M.E. (1993) Periportal fibrosis secondary to transfusion siderosis in two patients with acquired immune deficiency syndrome (AIDS) treated with zidovudine - a confusing ultrasound appearance. Clin. Radiol. 48, 125-126.
120. Whitcup, S.M., Dastgheib, K., Nussenblatt, R.B., Walton, R.C., Pizzo, P.A. and Chan, C.-C. (1994) A clinicopathologic report of the retinal lesions associated with didanosine. Arch. Ophthalmol. 112, 1594-1598.
121. Yarchoan, R., Mitsuya, H., Thomas, R.V., Pluda, J.M., Hartman, N.R., Perno, C.-F., Marczyk, K.S., Allain, J.-P., Johns, D.G. and Broder, S. (1989) In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 245, 412-415.
122. Youssef, J.A. and Badr, M.Z. (1992) Disruption of mitochondrial energetics and DNA synthesis by the anti-AIDS drug dideoxyinosine. Toxicol. Lett. 60, 197-202.